European Heart Journal

دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه

ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
~~قیمت : 3,800,000 تومان~~
قیمت ویژه : 1,900,000تومان

سفارش

The growing complexity of the number one killer: ischaemic heart disease

Filippo Crea

doi : 10.1093/eurheartj/ehab414

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2513–2517

خرید پکیج و مشاهده آنلاین مقاله

The link between regeneration and extracellular matrix in the heart—can three-dimensional in vitro models uncover it?

Sebastian Neuber, Timo Z Nazari-Shafti, Bramasta Nugraha, Volkmar Falk, Maximilian Y Emmert

doi : 10.1093/eurheartj/ehab079

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2518–2522

خرید پکیج و مشاهده آنلاین مقاله

A new evidence on pulmonary circulation discovery: A text of Ibn Luqa (860–912 AD)

Kamran Mahlooji, Mahsima Abdoli, Halil Tekiner, Arman Zargaran

doi : 10.1093/eurheartj/ehab039

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2522–2523

خرید پکیج و مشاهده آنلاین مقاله

Arrhythmias in the European Heart Journal

doi : 10.1093/eurheartj/ehab229

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Page 2524

خرید پکیج و مشاهده آنلاین مقاله

Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention?

Giovanna Liuzzo, Carlo Patrono

doi : 10.1093/eurheartj/ehab357

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2525–2526

خرید پکیج و مشاهده آنلاین مقاله

Emergency department management of patients with adult congenital heart disease: a consensus paper from the ESC Working Group on Adult Congenital Heart Disease, the European Society for Emergency Medicine (EUSEM), the European Association for Cardio-Thoracic Surgery (EACTS), and the Association for Acute Cardiovascular Care (ACVC)

Massimo Chessa, Margarita Brida, Michael A Gatzoulis, Gerhard-Paul Diller, Jolien W Roos-Hesselink, Konstantinos Dimopoulos, Wilhelm Behringer, Martin M?ckel, Alessandro Giamberti, Lorenzo Galletti, Susana Price, Helmut Baumgartner, Pastora Gallego, Oktay Tutarel

doi : 10.1093/eurheartj/ehab272

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2527–2535

Adult congenital heart disease (ACHD) patients represent a growing population with increasing use of acute emergency department (ED) care. Providing comprehensive ED care necessitates an understanding of the most common clinical scenarios to improve morbidity and mortality in this population. The aim of this position document is to provide a consensus regarding the management of the most common clinical scenarios of ACHD patients presenting to the ED.

خرید پکیج و مشاهده آنلاین مقاله

A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST)

Evangelos K Oikonomou, David Van Dijk, Helen Parise, Marc A Suchard, James de Lemos, Charalambos Antoniades, Eric J Velazquez, Edward J Miller, Rohan Khera

doi : 10.1093/eurheartj/ehab223

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2536–2548

Coronary artery disease is frequently diagnosed following evaluation of stable chest pain with anatomical or functional testing. A more granular understanding of patient phenotypes that benefit from either strategy may enable personalized testing.

خرید پکیج و مشاهده آنلاین مقاله

Precision medicine gets an ASSIST in diagnostic testing

Michael G Nanna, Pamela S Douglas

doi : 10.1093/eurheartj/ehab313

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2549–2551

خرید پکیج و مشاهده آنلاین مقاله

Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction

John Hung, Andreas Roos, Erik Kadesj?, David A McAllister, Dorien M Kimenai, Anoop S V Shah, Atul Anand, Fiona E Strachan, Keith A A Fox, Nicholas L Mills, Andrew R Chapman, Martin J Holzmann

doi : 10.1093/eurheartj/ehaa375

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2552–2561

The Global Registry of Acute Coronary Events (GRACE) score was developed to evaluate risk in patients with myocardial infarction. However, its performance in type 2 myocardial infarction is uncertain.

خرید پکیج و مشاهده آنلاین مقاله

Has the Fourth Universal Definition of Myocardial Infarction led to better diagnosis and risk stratification?

Héctor Bueno, Xavier Rossello, Alfredo Bardaj?

doi : 10.1093/eurheartj/ehaa486

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2562–2564

no abstract

خرید پکیج و مشاهده آنلاین مقاله

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Giulia Ferrannini, Hertzel Gerstein, Helen Martina Colhoun, Gilles R Dagenais, Rafael Diaz, Leanne Dyal, Mark Lakshmanan, Linda Mellbin, Jeffrey Probstfield, Matthew Casey Riddle, Jonathan Edward Shaw, Alvaro Avezum, Jan Neil Basile, William C Cushman, Petr Jansky, M?ty?s Keltai, Fernando Lanas, Lawrence Alan Leiter, Patricio Lopez-Jaramillo, Prem Pais, Valdis P?r?gs, Nana Pogosova, Peter Johann Raubenheimer, Wayne Huey-Herng Sheu, Lars Rydén

doi : 10.1093/eurheartj/ehaa777

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2565–2573

Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 receptor agonists and SGLT-2 inhibitors as initial glucose-lowering therapy. This is questioned since outcome trials of these drug classes had metformin as background therapy. In this post hoc analysis, the effect of dulaglutide on CV events was investigated according to the baseline metformin therapy by means of a subgroup analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.

خرید پکیج و مشاهده آنلاین مقاله

Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin

Naveed Sattar, Darren K McGuire

doi : 10.1093/eurheartj/ehaa879

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2574–2576

خرید پکیج و مشاهده آنلاین مقاله

Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease—a nationwide study

Maria Fedchenko, Zacharias Mandalenakis, Kok Wai Giang, Annika Rosengren, Peter Eriksson, Mikael Dellborg

doi : 10.1093/eurheartj/ehaa874

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2577–2586

We aimed to describe the risk of myocardial infarction (MI) in middle-aged and older patients with congenital heart disease (ACHD) and to evaluate the long-term outcomes after index MI in patients with ACHD compared with controls.

خرید پکیج و مشاهده آنلاین مقاله

Congenital heart defects as an intrinsic additional risk factor for the occurrence and outcome of myocardial infarction

Stefan Orwat, Gerhard-Paul Diller

doi : 10.1093/eurheartj/ehaa892

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2587–2589

no abstract

خرید پکیج و مشاهده آنلاین مقاله

Assessment and pathophysiology of microvascular disease: recent progress and clinical implications

Stefano Masi, Damiano Rizzoni, Stefano Taddei, Robert Jay Widmer, Augusto C Montezano, Thomas F Lüscher, Ernesto L Schiffrin, Rhian M Touyz, Francesco Paneni, Amir Lerman, Gaetano A Lanza, Agostino Virdis

doi : 10.1093/eurheartj/ehaa857

European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2590–2604

The development of novel, non-invasive techniques and standardization of protocols to assess microvascular dysfunction have elucidated the key role of microvascular changes in the evolution of cardiovascular (CV) damage, and their capacity to predict an increased risk of adverse events. These technical advances parallel with the development of novel biological assays that enabled the ex vivo identification of pathways promoting microvascular dysfunction, providing novel potential treatment targets for preventing cerebral-CV disease. In this article, we provide an update of diagnostic testing strategies to detect and characterize microvascular dysfunction and suggestions on how to standardize and maximize the information obtained from each microvascular assay. We examine emerging data highlighting the significance of microvascular dysfunction in the development CV disease manifestations. Finally, we summarize the pathophysiology of microvascular dysfunction emphasizing the role of oxidative stress and its regulation by epigenetic mechanisms, which might represent potential targets for novel interventions beyond conventional approaches, representing a new frontier in CV disease reduction.

خرید پکیج و مشاهده آنلاین مقاله